^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | ABM-1310 (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Excerpt:
...- Part A: Patients with advanced or metastatic solid tumors with documentation of positive BRAF V600E mutation, or any other BRAF V600 mutation is required for enrollment...
Trial ID:
Source:
Title:
A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors
Excerpt:
...Documentation of positive BRAF V600 mutation is required for enrollment....
Trial ID:
More C2 evidence
Source:
Title:
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
Excerpt:
...Documentation of positive BRAF V600 mutation is required for enrollment (the blood BRAF V600 test report is received at the dose-escalation stage)....
Trial ID:
Less C2 evidence
Source:
Title:
A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors.
Published date:
05/25/2023
Excerpt:
Among 16 efficacy evaluable pts, two (pleomorphic xanthoastrocytoma and glioblastoma) had a partial response (PR) and eight had stable disease (SD) as their best response...ABM-1310 at the currently tested doses up to 200 mg bid, either alone or in combination with cobimetinib, was generally well tolerated, with no new safety signals. Preliminary efficacy data demonstrate favorable activity of ABM-1310 in pts with BRAFv600-mutated solid tumors, including primary CNS tumors, and pts previously refractory to other BRAF/MEK inhibitors and I/O therapies.
DOI:
10.1200/JCO.2023.41.16_suppl.3098
Trial ID:
